Large-scale high-throughput screen for cardiac ryanodine receptor targeted therapeutics
Journal of Biological Chemistry · 2026
DOI: 10.1016/j.jbc.2025.110951 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2026. Verfasst von Roman Nikolaienko und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell and Molecular Physiology, Loyola University Chicago, Stritch School of Medicine, Maywood, Illinois, USA. Hauptthemen laut MEDLINE: Ryanodine Receptor Calcium Release Channel, High-Throughput Screening Assays, Small Molecule Libraries. Die Arbeit nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIA NIH HHS, NIAMS NIH HHS.
Abstract (Originalsprache)
In high-throughput screening (HTS) assays using fluorescence lifetime (FLT)-detected FRET, we have identified compounds that allosterically modulate the pathologically leaky ryanodine receptor (RyR) calcium release channels. These compounds may prevent or reduce the elevated Ca2+ that fuels arrhythmia, heart failure, and age-related neurodegeneration. RyRs are responsible for intracellular Ca2+ release from endoplasmic/sarcoplasmic reticulum (ER/SR). The resulting [Ca2+] pulse is a signal for many cellular processes, whereas sustained elevated [Ca2+] is pathologic. Our FRET-based HTS detects the pathology-linked RyR leaky state by monitoring binding of the accessory protein calmodulin and the DPc10 peptide (corresponding to RyR2 residues 2460-2495) known to perturb interdomain interactions within RyR2. Under conditions mimicking a pathological state, we have screened a 50,000-compound chemical library to identify small-molecule modulators of RyR2 in cardiac SR membranes. This screen yielded 603 compounds that reproducibly altered FRET. Based on FRET response profiles that align with therapeutic potential, 83 of those most promising compounds were purchased and validated by FRET dose response evaluation. Focusing on ten chemical scaffolds that desirably increase A-CaM binding, six representative compounds reduced RyR2 activity as measured by [3H]ryanodine binding. Ca2+ dynamics in HEK293 cells expressing human RyR2 or in cardiomyocytes highlighted the isoxazole group of hits as potentially therapeutic by targeting the pathological RyR2 leak state.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cell and Molecular Physiology, Loyola University Chicago, Stritch School of Medicine, Maywood, Illinois, USA.
- Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, Minnesota, USA.
- Department of Medicinal Chemistry, University of Minnesota, Minneapolis, Minnesota, USA.
- Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, Minnesota, USA; Photonic Pharma LLC, Minneapolis, Minnesota, USA.
- Photonic Pharma LLC, Minneapolis, Minnesota, USA.
- Department of Pharmacology, University of California at Davis, Davis, California, USA.
Förderung
- NHLBI NIH HHS
- NIA NIH HHS
- NIAMS NIH HHS
- National Heart Lung and Blood Institute
- National Institute on Aging
- National Institutes of Health
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
Zitieren
APA
Nikolaienko, R., Bovo, E., Solberg, J. C., Brinkmann, M., Treinen, L. M., Thompson, A. R., Berg, K., Thomas, D. D., Thomas, J. J., Bers, D. M., Aldrich, C. C., Zima, A. V., Cornea, R. L., & Rebbeck, R. T. (2026). Large-scale high-throughput screen for cardiac ryanodine receptor targeted therapeutics. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2025.110951
Vancouver
Nikolaienko R, Bovo E, Solberg JC, Brinkmann M, Treinen LM, Thompson AR, et al. Large-scale high-throughput screen for cardiac ryanodine receptor targeted therapeutics. Journal of Biological Chemistry. 2026. doi:10.1016/j.jbc.2025.110951
BibTeX
@article{Nikolaienko2026,
author = {Nikolaienko, Roman and Bovo, Elisa and Solberg, Jonathan C and Brinkmann, Marzena and Treinen, Levy M and Thompson, Andrew R and Berg, Kaja and Thomas, David D and Thomas, Jennifer J and Bers, Donald M and Aldrich, Courtney C and Zima, Aleksey V and Cornea, Razvan L and Rebbeck, Robyn T},
title = {Large-scale high-throughput screen for cardiac ryanodine receptor targeted therapeutics},
journal = {Journal of Biological Chemistry},
year = {2026},
doi = {10.1016/j.jbc.2025.110951}
}
EUVIMED